Champions Oncology Fiscal Q1 2027 Earnings: Margin Expansion Lifts Adjusted EBITDA

Champions Oncology (Nasdaq: CSBR) reported fiscal Q1 2027 revenue of $15.2 million for the quarter ended July 31, 2026, up 8.8% from $14.0 million, while GAAP basic EPS remained a loss of $0.03. Better conversion of contracted research work and increased data license revenue supported growth, while lower third-party radiolabeling costs helped lift the non-GAAP oncology services margin to 51%.

Core Financial Results

Revenue grew faster than total costs and operating expenses, which increased 7.7% to $15.6 million. That helped narrow the GAAP operating and net losses, although the company remained unprofitable on a reported basis.

The most pronounced improvement appeared in non-GAAP results: oncology services profit increased by approximately 28%, and adjusted EBITDA rose by $612,000. The following figures cover the three months ended July 31.

Adjusted EBITDA excludes stock-based compensation, depreciation and amortization, other income or expense, taxes, and any applicable equipment-disposal loss. Oncology services margin is also a non-GAAP measure based on oncology revenue less the direct cost of that revenue.

Business Performance

Core research services were the primary revenue driver. Champions attributed the improvement to better study execution and conversion of contracted work into recognized revenue, indicating that operational throughput—not just new contract activity—supported the quarter’s growth.

Data license revenue also increased, and management reported greater commercial activity around the company’s data offerings. However, Champions did not provide separate revenue figures for research services and data licensing, so their individual contributions cannot be quantified from the release.

The company continued investing in radiopharmaceutical capabilities, its data platform, target discovery initiatives, and an expanded commercial organization. These investments are intended to support growth across both research services and data licensing.

Margin Expansion Was Partly Reinvested, While Cash Conversion Weakened

Cost of oncology revenue declined 5.8% to $7.5 million even as revenue increased. Lower third-party radiolabeling costs contributed to the resulting eight-percentage-point expansion in oncology services margin, producing a larger improvement in direct profit than in revenue.

Part of that benefit was absorbed by higher operating expenses. Sales and marketing expense rose 66.6% to $3.1 million as Champions expanded its commercial organization. Research and development expense increased 12.6% to $2.3 million, primarily because of higher share-based compensation associated with Corellia, the company’s target-discovery subsidiary. General and administrative expense increased 4.0% to $2.7 million.

Stock-based compensation totaled $766,000, up from $208,000, while depreciation and amortization was $314,000. These adjustments explain much of the gap between the $426,000 GAAP net loss and positive adjusted EBITDA of $671,000.

Cash generation did not match the improvement in adjusted profitability. Champions used $492,000 of operating cash, compared with generating $600,000 a year earlier, mainly because accounts payable decreased and accounts receivable increased. Accounts receivable reached $13.6 million, up from $13.2 million at the end of fiscal 2026.

The company ended the quarter with $4.4 million in cash, down from $4.9 million on April 30, 2026, and reported no debt. Deferred revenue increased to $9.6 million from $8.8 million over the same period.

Management Perspective

CEO Robert Brainin attributed the quarter’s higher revenue and margins to improved execution and conversion in core research services. He also pointed to increased commercial activity around the company’s data offerings while emphasizing continued investment in the commercial organization, radiopharmaceutical capabilities, data platform, and target discovery.

CFO David Miller characterized the adjusted EBITDA increase as evidence of operating leverage as revenue grows. Management’s stated priorities remain revenue growth, expense discipline, and converting additional growth into improved profitability.

Recent Insider Transactions

The supplied insider data shows no insider purchases or sales during the latest six-month period and no net change in insider shares. Total insider holdings were listed at approximately 3.66 million shares.

Only two transactions were reported for the latest two-year period, both involving Director Joel Ackerman and both classified as direct conversions or exercises of derivative securities rather than open-market purchases or sales.

The supplied data labels the final figures as “Value” but does not specify their currency or whether they represent another unit. The transactions alone do not establish an insider’s view of the company’s prospects.

Risks Investors Should Watch

• Weak cash conversion: Operating cash flow moved from a $600,000 inflow to a $492,000 outflow because of working-capital movements. Continued increases in receivables or reductions in payables could place further pressure on the company’s $4.4 million cash balance.
• Higher commercial spending: Sales and marketing expense increased substantially as Champions expanded its commercial organization. Revenue growth must continue converting into higher direct profit for these investments to support overall profitability.
• Margin sensitivity: The improvement in oncology services margin partly reflected lower third-party radiolabeling costs, making future direct profitability sensitive to these outside costs as well as study execution.
• GAAP and adjusted-profit divergence: Stock-based compensation rose to $766,000 and represented a significant adjustment to EBITDA. Champions remained loss-making under GAAP despite reporting positive adjusted EBITDA and adjusted EPS.
• Execution of growth initiatives: Management is investing simultaneously in research services, data licensing, radiopharmaceutical capabilities, and target discovery. The financial return from these initiatives depends on sustained study conversion and expansion of the data customer base.

Summary

Champions Oncology’s fiscal Q1 2027 results showed improved research-services execution, higher data license revenue, and a meaningful expansion in direct service margins. Those gains lifted adjusted EBITDA and narrowed the GAAP operating loss, but higher commercial investment and working-capital outflows limited the improvement in reported earnings and cash flow. Future quarters will show whether the company can sustain its higher service margin, convert receivables into cash, and generate enough growth from its expanded commercial and data initiatives to reach consistent GAAP profitability.